A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia

DiBonaventura, Marco; Gabriel, Susan; Dupclay, Leon; Gupta, Shaloo; Kim, Edward

doi:10.1186/1471-244x-12-20

Cited by 333Medication Adherence and ComplianceSchizophrenia research and treatmentBipolar Disorder and Treatment

A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia

Open access

DiBonaventura, Marco, Gabriel, Susan, Dupclay, Leon, Gupta, Shaloo, Kim, Edward·2012·BMC Psychiatry

DOI 10.1186/1471-244x-12-20PMC PMC3342101

Open this paper in CoChat — free account Open PDF

Abstract

BACKGROUND: Antipsychotic medications often have a variety of side effects, however, it is not well understood how the presence of specific side effects correlate with adherence in a real-world setting. The aim of the current study was to examine the relationship between these variables among community-dwelling patients with schizophrenia. METHODS: Data were analyzed from a 2007-2008 nationwide survey of adults who self-reported a diagnosis of schizophrenia and were currently using an antipsychotic medication (N = 876). The presence of side effects was defined as those in which the patient reported they were at least "somewhat bothered". Adherence was defined as a score of zero on the Morisky Medication Adherence Scale. To assess the relationship between side effects and adherence, individual logistic regression models were fitted for each side effect controlling for patient characteristics. A single logistic regression model assessed the relationship between side effect clusters and adherence. The relationships between adherence and health resource use were also examined. RESULTS: A majority of patients reported experiencing at least one side effect due to their medication (86.19%). Only 42.5% reported complete adherence. Most side effects were associated with a significantly reduced likelihood of adherence. When grouped as side effect clusters in a single model, extra pyramidal symptoms (EPS)/agitation (odds ratio (OR) = 0.57, p = 0.0007), sedation/cognition (OR = 0.70, p = 0.033), prolactin/endocrine (OR = 0.69, p = 0.0342), and metabolic side effects (OR = 0.64, p = 0.0079) were all significantly related with lower rates of adherence. Those who reported complete adherence to their medication were significantly less likely to report a hospitalization for a mental health reason (OR = 0.51, p = 0.0006), a hospitalization for a non-mental health reason (OR = 0.43, p = 0.0002), and an emergency room (ER) visit for a mental health reason (OR = 0.60, p = 0.008). CONCLUSIONS: Among patients with schizophrenia, medication side effects are highly prevalent and significantly associated with medication nonadherence. Nonadherence is significantly associated with increased healthcare resource use. Prevention, identification, and effective management of medication-induced side effects are important to maximize adherence and reduce health resource use in schizophrenia.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Integrity signals

Registry

Crossref · 10.1186/1471-244x-12-20

Cites

31 of 31 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Patients feeling dizziness, fatigue, tiredness, sedation, lethargy, and sleepiness were the most frequently reported side-effects that contributed to medication non-adherence in seven studies.
“In seven studies, patients feeling dizziness, fatigue, tiredness, sedation, lethargy, and sleepiness were the most frequently reported side-effects that contributed to medication non-adherence [11, 33, 36, 37, 50, 52, 65].”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [33]
Weight gain was a medication-related side-effect associated with medication non-adherence and patients' perception toward their medication in five studies.
“Likewise, in five studies, weight gain was another medication-related side-effect that associated with medication non-adherence and patients’ perception toward their medication [25, 33, 36, 44, 55].”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [33]
Side-effects such as decreased sexual interest and having a symptom of sexual dysfunction were associated with patients' medication adherence in two studies.
“In two studies, side-effects such as decreased sexual interest and having a symptom of sexual dysfunction were associated with patients’ medication adherence [33, 36].”
From Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis (2020) · cites this paper as [33]

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Effectiveness of Antipsychotic Drugs in Patients with Chronic Schizophrenia
Lieberman, J. A., Stroup, T. S., McEvoy, J. P., Swartz, M. S., Rosenheck, R. A., Perkins, D. O., Keefe, R. S. E., Davis, S. M., Davis, C. E., Lebowitz, B. D., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa051688 · Cited by 5,892 · see citing works
Concurrent and Predictive Validity of a Self-reported Measure of Medication Adherence
Morisky, D. E., Green, L. W., & Levine, D. M. (1986) · Medical Care · doi:10.1097/00005650-198601000-00007 · Cited by 5,304 · see citing works
Prevalence of and Risk Factors for Medication Nonadherence in Patients With Schizophrenia: A Comprehensive Review of Recent Literature
Lacro, J. P., Dunn, L. B., Dolder, C. R., Leckband, S. G., & Jeste, D. V. (2002) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v63n1007 · Cited by 1,383 · cited 2× · see citing works
“Prior evidence has suggested that longer illness duration is associated with greater adherence [30]; therefore, age may be serving as a proxy for years diagnosed.”
Background
Determinants of Medication Compliance in Schizophrenia: Empirical and Clinical Findings
Fenton, W. S., Blyler, C. R., & HEINSSEN, R. K. (1997) · Schizophrenia Bulletin · doi:10.1093/schbul/23.4.637 · Cited by 944 · see citing works
Atypical antipsychotic-induced metabolic side effects: insights from receptor-binding profiles
Nasrallah, H. A. (2007) · Molecular Psychiatry · doi:10.1038/sj.mp.4002066 · Cited by 716 · see citing works
Lifetime Prevalence, Demographic Risk Factors, and Diagnostic Validity of Nonaffective Psychosis as Assessed in a US Community Sample: The National Comorbidity Survey
Kendler, K. S. (1996) · Archives of General Psychiatry · doi:10.1001/archpsyc.1996.01830110060007 · Cited by 676 · see citing works
The Economic Burden of Schizophrenia in the United States in 2002
Wu, E. Q., Birnbaum, H. G., Shi, L., BALL, D. E., Kessler, R. C., Moulis, M., & Aggarwal, J. (2005) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v66n0906 · Cited by 614 · see citing works
Operational criteria and factors related to recovery from schizophrenia
Liberman, R. P., Kopelowicz, A. J., Ventura, J., & Gutkind, D. (2002) · International Review of Psychiatry · doi:10.1080/0954026021000016905 · Cited by 498 · see citing works
Obesity as a risk factor for antipsychotic noncompliance
Weiden, P. J., Mackell, J. A., & McDonnell, D. D. (2003) · Schizophrenia Research · doi:10.1016/s0920-9964(02)00498-x · Cited by 432 · see citing works
Self-reports of health care utilization compared to provider records
Ritter, P. L., Stewart, A. L., Kaymaz, H., Sobel, D. S., Block, D. A., & Lorig, K. R. (2001) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(00)00261-4 · Cited by 401 · see citing works
Prevalence and Incidence Studies of Schizophrenic Disorders: A Systematic Review of the Literature
Goldner, E. M., Hsu, L., Waraich, P. S., & Somers, J. M. (2002) · The Canadian Journal of Psychiatry · doi:10.1177/070674370204700904 · Cited by 340 · see citing works
The cost diary
Goossens, M. E. J. B., Mölken, M. R., Vlaeyen, J. W. S., & van der Linden, S. (2000) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(99)00177-8 · Cited by 335 · see citing works
Epidemiology of Schizophrenia: Review of Findings and Myths
Messias, E., Chen, C., & Eaton, W. W. (2007) · Psychiatric Clinics of North America · doi:10.1016/j.psc.2007.04.007 · Cited by 310 · see citing works
The National Comorbidity Survey
Kessler, R. C., & Walters, E. E. (2002) · Wiley eBooks · doi:10.1002/0471234311.ch14 · Cited by 305 · see citing works
Quality of life in caregivers of patients with schizophrenia: A literature review
Caqueo‐Urízar, A., Gutiérrez‐Maldonado, J., & Miranda‐Castillo, C. (2009) · Health and Quality of Life Outcomes · doi:10.1186/1477-7525-7-84 · Cited by 261 · see citing works
Review and analysis of hospitalization costs associated with antipsychotic nonadherence in the treatment of schizophrenia in the United States
Sun, S. X., Liu, G. G., Christensen, D. B., & Fu, A. Z. (2007) · Current Medical Research and Opinion · doi:10.1185/030079907x226050 · Cited by 196 · see citing works
Agreement between Self‐reported and Routinely Collected Health‐care Utilization Data among Seniors
Raina, P. S., Torrance-Rynard, V., Wong, M., & Woodward, C. A. (2002) · Health Services Research · doi:10.1111/1475-6773.00047 · Cited by 180 · see citing works
THE ACCURACY OF SELF-REPORTED HEALTHCARE RESOURCE UTILIZATION IN HEALTH ECONOMIC STUDIES
Petrou, S., Murray, L., Cooper, P., & Davidson, L. L. (2002) · International Journal of Technology Assessment in Health Care · doi:10.1017/s026646230200051x · Cited by 154 · see citing works
A Prospective Study of Risk Factors for Nonadherence With Antipsychotic Medication in the Treatment of Schizophrenia
Ascher‐Svanum, H., Zhu, B., Faries, D. E., Lacro, J. P., & Dolde, C. R. (2006) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.v67n0715 · Cited by 147 · see citing works
Dropout Rates in Placebo-Controlled and Active-Control Clinical Trials of Antipsychotic Drugs
Kemmler, G., Hummer, M., Widschwendter, C. G., & Fleischhacker, W. W. (2005) · Archives of General Psychiatry · doi:10.1001/archpsyc.62.12.1305 · Cited by 146 · see citing works
Strategies for Improving Treatment Adherence in Schizophrenia and Schizoaffective Disorder
GOFF, D. C., Hill, M. B., & Freudenreich, O. (2010) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.9096su1cc.04 · Cited by 136 · see citing works
The SOHO (Schizophrenia Outpatient Health Outcome) Study
Haro, J. M., & Salvador‐Carulla, L. (2006) · CNS Drugs · doi:10.2165/00023210-200620040-00003 · Cited by 84 · see citing works
Burden of schizophrenia in recently diagnosed patients: healthcare utilisation and cost perspective
Nicholl, D., Akhras, K. S., Diels, J., & Schadrack, J. (2010) · Current Medical Research and Opinion · doi:10.1185/03007991003658956 · Cited by 83 · see citing works
Describing an Atypical Antipsychotic: Receptor Binding and Its Role in Pathophysiology
Stahl, S. M. (2003) · The Primary Care Companion to The Journal of Clinical Psychiatry · Cited by 75 · see citing works
Strategies for improving adherence to second generation antipsychotics in patients with schizophrenia by increasing ease of use
BURTON, S. C. (2005) · Journal of Psychiatric Practice · doi:10.1097/00131746-200511000-00003 · Cited by 68 · see citing works
Good agreement between questionnaire and administrative databases for health care use and costs in patients with osteoarthritis
Pinto, D., Robertson, M. C., Hansen, P., & Abbott, J. (2011) · BMC Medical Research Methodology · doi:10.1186/1471-2288-11-45 · Cited by 64 · see citing works
A review of atypical antipsychotic drugs versus conventional medication in schizophrenia
Luft, B., & Taylor, D. M. (2006) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.7.13.1739 · Cited by 52 · see citing works
Adherence and outcomes associated with copayment burden in schizophrenia: a cross-sectional survey
Kim, E., Gupta, S., Bolge, S. C., Chen, C., Whitehead, R. E., & Bates, J. A. (2010) · Journal of Medical Economics · doi:10.3111/13696991003723023 · Cited by 36 · see citing works
Self-citation
Comparison of Patient and Clinician Perspectives in the Assessment of Antipsychotic Medication Adherence
Barbui, C., Kikkert, M., Mazzi, M. A., Becker, T. M., Bindman, J. P., Schene, A. H., Nosè, M., Helm, H., Thornicroft, G., & Tansella, M. (2009) · Psychopathology · doi:10.1159/000232973 · Cited by 33 · see citing works
Impact of psychotic relapse definitions in assessing drug efficacy and costs: comparison of quetiapine XR, olanzapine and paliperidone ER
Knapp, M. R. J., Locklear, J. C., & Järbrink, K. (2009) · Current Medical Research and Opinion · doi:10.1185/03007990903010623 · Cited by 10 · see citing works
The association of well-being, productivity and resource use among community-dwelling patients with schizophrenia using atypical antipsychotics
DiBonaventura, M., Panish, J. M., Kenworthy, D., Wagner, J.-S., & Dirani, R. D. (2010) · Journal of Pharmaceutical Health Services Research · doi:10.1111/j.1759-8893.2010.00033.x · Cited by 2 · see citing works
Self-citation

Flagged first, then by citations

Sorted by citations

Psychotropic medication non-adherence and its associated factors among patients with major psychiatric disorders: A systematic review and meta-analysis
Semahegn, A., Torpey, K., Manu, A., Assefa, N., Tesfaye, G., & Ankomah, A. (2020) · Systematic Reviews · doi:10.1186/s13643-020-1274-3 · Cited by 555 · see citing works
“USA [43] MA was 51.9%.”
BackgroundInfluential
Non-adherence to medication in patients with psychotic disorders: epidemiology, contributing factors and management strategies
Kane, J. M., Kishimoto, T., & Correll, C. U. (2013) · World Psychiatry · doi:10.1002/wps.20060 · Cited by 520 · see citing works
“Schizophrenia, USA (16) 876 Naturalistic Self-report 48.”
Influential
Why do psychiatric patients stop antipsychotic medication? A systematic review of reasons for nonadherence to medication in patients with serious mental illness
Velligan, D. I., Sajatovic, M., Hatch, A., Kramata, P., & Docherty, J. (2017) · Patient Preference and Adherence · doi:10.2147/ppa.s124658 · Cited by 333 · see citing works
Impact of long-acting injectable antipsychotics on medication adherence and clinical, functional, and economic outcomes of schizophrenia
Kaplan, G., Casoy, J., & Zummo, J. (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s53795 · Cited by 201 · see citing works
“A cross-sectional survey of patients with schizophrenia found that side effects to antipsychotic drugs were highly prevalent, and medication nonadherence was significantly associated with the occurrence of these side effects.(72) In addition, medication nonadherence was significantly associated with increased health c…”
The nocebo effect: patient expectations and medication side effects
Faasse, K., & Petrie, K. J. (2013) · Postgraduate Medical Journal · doi:10.1136/postgradmedj-2012-131730 · Cited by 191 · see citing works
The impact of severe mental disorders and psychotropic medications on sexual health and its implications for clinical management
Montejo, A. L., Montejo, L., & Baldwin, D. S. (2018) · World Psychiatry · doi:10.1002/wps.20509 · Cited by 191 · see citing works
Efficacy and safety of lurasidone 80 mg/day and 160 mg/day in the treatment of schizophrenia: A randomized, double-blind, placebo- and active-controlled trial
Loebel, A. D., Cucchiaro, J. B., Sarma, K., Xu, L., Hsu, C., Kalali, A. H., Pikalov, A., & Potkin, S. G. (2013) · Schizophrenia Research · doi:10.1016/j.schres.2013.01.009 · Cited by 170 · see citing works
Antipsychotic dose, dopamine D2 receptor occupancy and extrapyramidal side-effects: a systematic review and dose-response meta-analysis
Siafis, S., Wu, H., Wang, D., Burschinski, A., Nomura, N., Takeuchi, H., Schneider‐Thoma, J., Davis, J. M., & Leucht, S. (2023) · Molecular Psychiatry · doi:10.1038/s41380-023-02203-y · Cited by 166 · see citing works
“They can be stigmatizing and unpleasant, leading to nonadherence to treatment and the subsequent negative impacts [3].”
Background
Systematic literature review of schizophrenia clinical practice guidelines on acute and maintenance management with antipsychotics
Correll, C. U., Martin, A. L., Patel, C. A., Benson, C. J., Goulding, R., Sliwa, J. K., Joshi, K., Schiller, E., & Kim, E. (2022) · Schizophrenia · doi:10.1038/s41537-021-00192-x · Cited by 153 · see citing works
Self-citation
Barriers and facilitators of adherence to antidepressants among outpatients with major depressive disorder: A qualitative study
Ho, S. C., Jacob, S. A., & Tangiisuran, B. (2017) · PLOS ONE · doi:10.1371/journal.pone.0179290 · Cited by 129 · see citing works
Antipsychotic-induced hyperprolactinemia: synthesis of world-wide guidelines and integrated recommendations for assessment, management and future research
Grigg, J., Worsley, R., Thew, C., Gurvich, C., Thomas, N., & Kulkarni, J. (2017) · Psychopharmacology · doi:10.1007/s00213-017-4730-6 · Cited by 124 · see citing works
“This is concerning, since population-based data from patients with schizophrenia have shown PRL-related side effects to be significantly associated with medication nonadherence (DiBonaventura et al., 2012).”
Background
The Role of the Oral Microbiota Related to Periodontal Diseases in Anxiety, Mood and Trauma- and Stress-Related Disorders
Martínez, M., Postolache, T. T., García‐Bueno, B., Leza, J. C., Figuero, E., Lowry, C. A., & Malan‐Müller, S. (2022) · Frontiers in Psychiatry · doi:10.3389/fpsyt.2021.814177 · Cited by 127 · see citing works
“Adherence to psychiatric medications is further hindered by their side-effect profiles (5), and, due to the limited efficacy of antidepressants, nearly a third of patients do not respond to treatment (6).”
Background
Keeping up with the therapeutic advances in schizophrenia: a review of novel and emerging pharmacological entities
Krogmann, A., Peters, L., von Hardenberg, L., Bödeker, K., Nöhles, V. B., & Correll, C. U. (2019) · CNS Spectrums · doi:10.1017/s109285291900124x · Cited by 116 · see citing works
Strategies to improve medication adherence in patients with schizophrenia: the role of support services
El-Mallakh, P. L., & Findlay, L. (2015) · Neuropsychiatric Disease and Treatment · doi:10.2147/ndt.s56107 · Cited by 98 · see citing works
“Metabolic side effects of atypical antipsychotics, including weight gain, further contribute to lack of adherence.(17) However, some research suggests that recognition of the benefits of medications in alleviating troublesome psychotic symptoms improves willingness to tolerate the side-effect burden for the sake of me…”
Influential
The nocebo effect: a clinical challenge in the era of biosimilars
Pouillon, L., Socha, M., Demoré, B., Thilly, N., Abitbol, V., Danese, S., & Peyrin‐Biroulet, L. (2018) · Expert Review of Clinical Immunology · doi:10.1080/1744666x.2018.1512406 · Cited by 87 · see citing works
Risk and protective factors for relapse among Individuals with Schizophrenia: A Qualitative Study in Dar es Salaam, Tanzania
Sariah, A., Outwater, A. H., & Yahya-Malima, K. I. (2014) · BMC Psychiatry · doi:10.1186/s12888-014-0240-9 · Cited by 83 · see citing works
“Patients in Dar es Salaam reported sedation and exrapyramidal side effects such as rigidity, and tremors, which is consistent with prior research [14,15].”
Activating and Sedating Adverse Effects of Second-Generation Antipsychotics in the Treatment of Schizophrenia and Major Depressive Disorder: Absolute Risk Increase and Number Needed to Harm
Citrome, L. (2017) · Journal of Clinical Psychopharmacology · doi:10.1097/jcp.0000000000000665 · Cited by 92 · see citing works
“Among the most common adverse events (AEs) reported were restlessness (28%), insomnia (28%), and sleepiness (25%), at rates that were on par with weight gain (26%) and difficulty thinking/concentrating (32%).(6) For individual patients, preferences can vary regarding which type of adverse effect is least desired.”
BackgroundResult
Knowledge, attitudes and beliefs of patients and carers regarding medication adherence: a review of qualitative literature
Kelly, M., McCarthy, S., & Sahm, L. J. (2014) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-014-1761-3 · Cited by 78 · see citing works
“The negative impact of side effects upon adherence concurs with findings from other studies [54, 55].”
Factors influencing medication adherence among patients with severe mental disorders from the perspective of mental health professionals
Deng, M., Zhai, S., Ouyang, X., Liu, Z., & Ross, B. (2022) · BMC Psychiatry · doi:10.1186/s12888-021-03681-6 · Cited by 75 · see citing works
“Second, psychotropic medications like antipsychotics or antidepressants may introduce certain side effects, such as drowsiness, weight gain, diabetes, or sexual dysfunction, which might impact patients’ daily functioning and directly decrease their medication adherence [43].”
Background
Cryo-EM: the resolution revolution and drug discovery
de Oliveira, T. M., van Beek, L., Shilliday, F., Debreczeni, J. É., & Phillips, C. (2021) · SLAS DISCOVERY · doi:10.1177/2472555220960401 · Cited by 73 · see citing works
The impact on functioning of second-generation antipsychotic medication side effects for patients with schizophrenia: a worldwide, cross-sectional, web-based survey
Tandon, R., Lenderking, W. R., Weiss, C., Shalhoub, H., Barbosa, C. D., Chen, J., Greene, M., Meehan, S. R., Bouérat, L., Arango, C., et al. (2020) · Annals of General Psychiatry · doi:10.1186/s12991-020-00292-5 · Cited by 73 · see citing works
Does Switching Antipsychotics Ameliorate Weight Gain in Patients With Severe Mental Illness? A Systematic Review and Meta-analysis
Siskind, D. J., Gallagher, E., Winckel, K., Hollingworth, S., Kisely, S. R., Firth, J., Correll, C. U., & Marteene, W. (2020) · Schizophrenia Bulletin · doi:10.1093/schbul/sbaa191 · Cited by 76 · see citing works
Comparative Tolerability of Dopamine D2/3 Receptor Partial Agonists for Schizophrenia
Keks, N. A., Hope, J., Schwartz, D., McLennan, H., Copolov, D., & Meadows, G. N. (2020) · CNS Drugs · doi:10.1007/s40263-020-00718-4 · Cited by 71 · see citing works
“Useful in acute psychosis for anxiety, agitation and insomnia, somnolence can be seriously troublesome in longer term treatment, complicating recovery and return to usual functioning and resulting in poor adherence [92].”
Background
Non-Coding RNA as Novel Players in the Pathophysiology of Schizophrenia
Gibbons, A. S., Udawela, M., & Dean, B. (2018) · Non-Coding RNA · doi:10.3390/ncrna4020011 · Cited by 64 · see citing works
“Therefore, identifying biomarkers that predict a patient’s adverse response to antipsychotics could be useful indicators of potential non-adherence [133].”
Background
What is the impact of antidepressant side effects on medication adherence among adult patients diagnosed with depressive disorder: A systematic review
Niarchou, E., Roberts, L., & Naughton, B. D. (2024) · Journal of Psychopharmacology · doi:10.1177/02698811231224171 · Cited by 71 · see citing works
“…demonstrated suboptimal levels of adherence to medication in various chronic conditions such as hypertension (Tedla and Bautista, 2016) and HIV (Zhang et al., 2016) as well as in several mental health conditions such as schizophrenia (DiBonaventura et al., 2012) and depression (Ho et al., 2017).”
Background
Muscarinic Receptor Activators as Novel Treatments for Schizophrenia
Paul, S. M., Yohn, S. E., Brannan, S. K., Neugebauer‎, N. M., & Breier, A. F. (2024) · Biological Psychiatry · doi:10.1016/j.biopsych.2024.03.014 · Cited by 61 · see citing works
“Further, substantial side effects associated with current treatments, including sedation, extrapyramidal motor symptoms (EPSs), akathisia, prolactin elevation, and weight gain, all have been shown to contribute to poor adherence and subsequent relapse (5).”
Patient preferences concerning the efficacy and side-effect profile of schizophrenia medications: a survey of patients living with schizophrenia
Achtyes, E. D., Simmons, A., Skabeev, A., Levy, N., Jiang, Y., Marcy, P., & Weiden, P. J. (2018) · BMC Psychiatry · doi:10.1186/s12888-018-1856-y · Cited by 57 · see citing works
Consenso español sobre los riesgos y detección de la hiperprolactinemia iatrogénica por antipsicóticos
Montejo, Á. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo-Facorro, B., Cruz, J. J., del Pino, J., García Escudero, M. A., García Rizo, C., González-Pinto, A., et al. (2016) · Revista de Psiquiatría y Salud Mental · doi:10.1016/j.rpsm.2015.11.003 · Cited by 55 · see citing works
“There was an initial meeting of a group of 18 experts in Psychiatry (15), Endocrinology (1), Internal Medicine (1) and Oncology (1) chosen by the consensus coordinator and coming from different areas of Spain, all having scientific impact and being from the clinical, research and academic environment.”
Background
Long-Acting Injectable Antipsychotics in Schizophrenia: Literature Review and Practical Perspective, with a Focus on Aripiprazole Once-Monthly
Biagi, E., Capuzzi, E., Colmegna, F., Mascarini, A., Brambilla, G., Ornaghi, A., Santambrogio, J., & Clerici, M. (2017) · Advances in Therapy · doi:10.1007/s12325-017-0507-x · Cited by 54 · see citing works
“Similarly, patients completely adherent to their antipsychotic medication are at significantly reduced risk of hospitalization or emergency room visits for a mental health reason [20].”
Background
Understanding treatment non-adherence in schizophrenia and bipolar disorder: a survey of what service users do and why
Gibson, S., Brand, S. L., Burt, S., Boden, Z., & Benson, O. (2013) · BMC Psychiatry · doi:10.1186/1471-244x-13-153 · Cited by 53 · see citing works
“In their review, Clatworthy et al [9] found that concerns about side-effects were associated with nonadherence in bipolar disorder and DiBoventura et al [19] found a significant association between self-reported side effects and non-adherence in people with schizophrenia, in particular extra pyramidal symptoms and agi…”
Background
Medication adherence among patients with chronic conditions in Italy
Napolitano, F., Napolitano, P., Angelillo, I. F., & Collaborative Working Group (2015) · European Journal of Public Health · doi:10.1093/eurpub/ckv147 · Cited by 53 · see citing works
A Naturalistic Study of the Effectiveness of Pharmacogenetic Testing to Guide Treatment in Psychiatric Patients With Mood and Anxiety Disorders
Brennan, F. X., Gardner, K. R., Lombard, J., Perlis, R. H., D, M. F. M., Harris, H. W., & Scott, R. (2015) · The Primary Care Companion For CNS Disorders · doi:10.4088/pcc.14m01717 · Cited by 51 · see citing works
Efficacy, tolerability, and safety of xanomeline-trospium chloride for schizophrenia: A systematic review and meta-analysis
Fabiano, N., Wong, S., Zhou, C., Correll, C. U., Højlund, M., & Solmi, M. (2024) · European Neuropsychopharmacology · doi:10.1016/j.euroneuro.2024.11.013 · Cited by 47 · see citing works
“…Burschinski et al., 2023; Solmi et al., 2024), which is also associated with poorer quality of life and greater nonadherence (Tandon et al., 2020; Dibonaventura et al., 2012) as well as with long-term cardiovascular and mortality risk (Vancampfort et al., 2015; Vancampfort et al., 2016; Correll…”
Making decisions about antipsychotics: a qualitative study of patient experience and the development of a decision aid
Kaar, S. J., Gobjila, C., Butler, E., Henderson, C., & Howes, O. D. (2019) · BMC Psychiatry · doi:10.1186/s12888-019-2304-3 · Cited by 46 · see citing works
The give and take of freedom: The role of involuntary hospitalization and treatment in recovery from mental illness
Danzer, G. S., & Wilkus-Stone, A. (2015) · Bulletin of the Menninger Clinic · doi:10.1521/bumc.2015.79.3.255 · Cited by 43 · see citing works
“This 1% of the population was associated with $63 billion in healthcare costs (DiBonaventura et al., 2012).”
Background
Relative bioavailability and safety of aripiprazole lauroxil, a novel once-monthly, long-acting injectable atypical antipsychotic, following deltoid and gluteal administration in adult subjects with schizophrenia
Turncliff, R. Z., Hard, M., Du, Y., Risinger, R. C., & Ehrich, E. W. (2014) · Schizophrenia Research · doi:10.1016/j.schres.2014.09.021 · Cited by 43 · see citing works
“Side effects of antipsychotics including extrapyramidal symptoms, weight gain and cognitive impairment contribute to nonadherence (Ascher-Svanum et al., 2006, 2009; DiBonaventura et al., 2012).”
Management Strategies for Antipsychotic-Related Sexual Dysfunction: A Clinical Approach
Montejo, A. L., de Alarcón, R., Prieto, N., Acosta, J. M., Buch-Vicente, B., & Montejo, L. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10020308 · Cited by 43 · see citing works
Comparing cognitive functions in medication adherent and non-adherent patients with schizophrenia
El-Missiry, A., Elbatrawy, A. N., Missiry, M. E., Moneim, D. A., Ali, R., & Essawy, H. (2015) · Journal of Psychiatric Research · doi:10.1016/j.jpsychires.2015.09.006 · Cited by 42 · see citing works
A Comparison of Topical Corticosteroids and Topical Calcineurin Inhibitors for the Treatment of Atopic Dermatitis
Pena, J., Zameza, P. A., Pixley, J. N., Remitz, A., & Feldman, S. R. (2023) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2023.03.022 · Cited by 41 · see citing works
Approaches to improve adherence to pharmacotherapy in patients with schizophrenia
Shuler, K. M. (2014) · Patient Preference and Adherence · doi:10.2147/ppa.s59371 · Cited by 41 · see citing works
“In patients with schizophrenia, nonadherence to prescribed medication is associated with symptom relapse, increased hospitalizations, and increased health care costs.(10,11) Given the prevalence and impact of medication non-”
Assessing the clinical impact of CYP2C9 pharmacogenetic variation on phenytoin prescribing practice and patient response in an integrated health system
Fohner, A. E., Ranatunga, D. K., Thai, K. K., Lawson, B. L., RISCH, N. J., Oni‐Orisan, A., Jelalian, A. T., Rettie, A. E., Liu, V. X., & Schaefer, C. A. (2019) · Pharmacogenetics and Genomics · doi:10.1097/fpc.0000000000000383 · Cited by 40 · see citing works
Spanish consensus on the risks and detection of antipsychotic drug-related hyperprolactinaemia
Montejo, A. L., Arango, C., Bernardo, M., Carrasco, J. L., Crespo‐Facorro, B., Cruz, J. J., del Pino, J., Escudero, M. A. G., García‐Rizo, C., González-Pinto, A. M., et al. (2016) · Revista de Psiquiatría y Salud Mental (English Edition) · doi:10.1016/j.rpsmen.2016.06.001 · Cited by 40 · see citing works
Initiation of aripiprazole once-monthly in patients with schizophrenia
Raoufinia, A., Baker, R. A., Eramo, A., Nylander, A., Landsberg, W., Kostic, D., & Larsen, F. (2015) · Current Medical Research and Opinion · doi:10.1185/03007995.2015.1006356 · Cited by 37 · see citing works
Why are long-acting injectable antipsychotics still underused?
Bosanac, P., & Castle, D. (2015) · BJ Psych Advances · doi:10.1192/apt.bp.114.013565 · Cited by 35 · see citing works
Comparison and predictors of treatment adherence and remission among patients with schizophrenia treated with paliperidone palmitate or atypical oral antipsychotics in community behavioral health organizations
ANDERSON, J. P., Icten, Z., Alas, V., Benson, C. J., & Joshi, K. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1507-8 · Cited by 37 · see citing works
A systematic review of clinical guidelines on choice, dose, and duration of antipsychotics treatment in first- and multi-episode schizophrenia
Hui, C. L. M., Lam, B. S. T., Lee, E. H. M., Chan, S. K. W., Chang, W. C., Suen, Y. N., & Chen, E. Y. H. (2019) · International Review of Psychiatry · doi:10.1080/09540261.2019.1613965 · Cited by 36 · see citing works
Long‐term safety and effectiveness of brexpiprazole in Japanese patients with schizophrenia: A 52‐week, open‐label study
Ishigooka, J., Iwashita, S., & Tadori, Y. (2018) · Psychiatry and Clinical Neurosciences · doi:10.1111/pcn.12654 · Cited by 35 · see citing works
“These side-effects may worsen the patient’s ability to function, diminish subjective well-being and quality of life, and contribute to poor treatment adherence.(6,7) Brexpiprazole is approved in the USA, Canada, Australia, and Japan for the treatment of schizophrenia and in the USA as adjunctive treatment of major dep…”
Background
Holistic prevention and management of physical health side-effects of psychotropic medication: second report of the Lancet Psychiatry Physical Health Commission
Halstead, S., Yap, C. X., Warren, N., Agarwal, S. M., Brand, B. A., Chan, S. K. W., Cipriani, A., Correll, C. U., Crossley, N. A., D’Ambrosio, E., et al. (2025) · The Lancet Psychiatry · doi:10.1016/s2215-0366(25)00162-2 · Cited by 38 · see citing works
Safety and tolerability of lumateperone 42 mg: An open-label antipsychotic switch study in outpatients with stable schizophrenia
Correll, C. U., Vanover, K. E., Davis, R. E., Chen, R., Satlin, A., & Mates, S. L. (2021) · Schizophrenia Research · doi:10.1016/j.schres.2020.12.006 · Cited by 33 · see citing works
“, 2017) are also associated with nonadherence (DiBonaventura et al., 2012; Kane et al., 2013) and reduced quality of life (Briggs et al.”
Prevalence and management practice of first generation antipsychotics induced side effects among schizophrenic patients at Amanuel Mental Specialized Hospital, central Ethiopia: cross-sectional study
Wubeshet, Y. S., Muhammed, O. S., & Desse, T. A. (2019) · BMC Psychiatry · doi:10.1186/s12888-018-1999-x · Cited by 35 · see citing works
A systematic review on sex differences in adverse drug reactions related to psychotropic, cardiovascular, and analgesic medications
Shan, Y., Cheung, L., Zhou, Y., Huang, Y., & Huang, R. S. (2023) · Frontiers in Pharmacology · doi:10.3389/fphar.2023.1096366 · Cited by 32 · see citing works
Randomized controlled trial of the effects of nursing care based on a telephone intervention for medication adherence in schizophrenia
Uslu, E., & Buldukoğlu, K. (2019) · Perspectives In Psychiatric Care · doi:10.1111/ppc.12376 · Cited by 32 · see citing works
Co‐administration of probiotic and vitamin D significantly improves cognitive function in schizophrenic patients: A double‐blinded randomized controlled trial
Mohammadi, A., Sadighi, G., Astaneh, A. N., Ebrahimi, M. T., & Dejam, T. (2024) · Neuropsychopharmacology Reports · doi:10.1002/npr2.12431 · Cited by 31 · see citing works
“5,6 Taking antipsychotic drugs, which have anticholinergic and anti-histaminergic effects, increases the prevalence of constipation and weight gain-related disorders in schizophrenic patients.”
Background
Long-acting injectable second-generation antipsychotics in first-episode psychosis
Salgueiro, M., & Segarra, R. (2018) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000249 · Cited by 31 · see citing works
“Therefore, LAI risperidone improved the adherence to treatment and decreased the relapse rate in FEP patients more than oral antipsychotics, a key factor in the treatment of psychotic disorders (Dibonaventura et al., 2012; Hasan et al., 2013).”
Background
Using Long-acting Injectable Antipsychotics to Enhance the Potential for Recovery in Schizophrenia
Correll, C. U., & Lauriello, J. (2020) · The Journal of Clinical Psychiatry · doi:10.4088/jcp.ms19053ah5c · Cited by 31 · see citing works
Association between antipsychotic medication and clinically relevant weight change: meta-analysis
Campforts, B. C. M., Drukker, M., Crins, J., van Amelsvoort, T., & Bak, M. (2023) · BJPsych Open · doi:10.1192/bjo.2022.619 · Cited by 32 · see citing works
Why maximum tolerated dose?
Stampfer, H. G., Gabb, G. M., & Dimmitt, S. B. (2019) · British Journal of Clinical Pharmacology · doi:10.1111/bcp.14032 · Cited by 29 · see citing works
“Adverse effects reduce adherence.(35) Patients should probably not be left on psychotropics, TABLE 1 Approved, maximum and ED50 doses of common central nervous system and cardiovascular system drugs”
Background
Daily functioning and symptom factors contributing to attitudes toward antipsychotic treatment and treatment adherence in outpatients with schizophrenia spectrum disorders
Leijala, J., Kampman, O., Suvisaari, J., & Eskelinen, S. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03037-0 · Cited by 29 · see citing works
“Factors such as poor insight [13–18], substance abuse [14, 17, 19, 20], negative attitudes toward medication [9, 13, 17, 21, 22] and side-effects [19, 23] have been associated with non-adherence.”
Background
Understanding the medication safety challenges for patients with mental illness in primary care: a scoping review
Ayre, M. J., Lewis, P. J., & Keers, R. N. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04850-5 · Cited by 31 · see citing works
Australian mental health nurses’ perspectives about the identification and management of antipsychotic medication side effects: a cross-sectional survey
Morrison, P., Stomski, N. J., & Meehan, T. (2016) · Journal of Mental Health · doi:10.1080/09638237.2016.1222060 · Cited by 28 · see citing works
“reported by almost four in five mental health consumers taking antipsychotic medication (Dibonaventura et al., 2012).”
Background
Commercial Devices-Based System Designed to Improve the Treatment Adherence of Hypertensive Patients
da Silva, V. J., Souza, V. D. S., da Cruz, R. G., de Lucena, J. M. V. M., Jazdi, N., & de Lucena, V. F. (2019) · Sensors · doi:10.3390/s19204539 · Cited by 28 · see citing works
“The main issue is that many factors contribute to abandoning medical treatment, such as unpleasant side effects [24], a lack of involvement from relatives and caregivers [25], and forgetfulness [12].”
Background
Predictors of emergency department visits for suicidal ideation and suicide attempt
Gentil, L., Huỳnh, C., Grenier, G., & Fleury, M. (2020) · Psychiatry Research · doi:10.1016/j.psychres.2020.112805 · Cited by 27 · see citing works
Efficacy and Safety of Long Acting Injectable Atypical Antipsychotics: A Review
Berardis, D. D., Marini, S., Carano, A., Lang, A., Cavuto, M., Piersanti, M., Fornaro, M., Perna, G., Valchera, A., Mazza, M., et al. (2013) · Current Clinical Pharmacology · doi:10.2174/15748847113089990056 · Cited by 27 · see citing works
The impact of negative treatment experiences on persistent refusal of antipsychotics
Lincoln, T. M., Jung, E., Wiesjahn, M., Wendt, H., Bock, T. A., & Schlier, B. (2016) · Comprehensive Psychiatry · doi:10.1016/j.comppsych.2016.07.009 · Cited by 27 · see citing works
“Negative previous experiences with medication, such as non-response [27] or severe side effects [28] are also likely to influence the decision of whether to accept medication as does a generalized critical attitude towards medication [4,29,30].”
Background
Treatment outcomes in schizophrenia: qualitative study of the views of family carers
Lloyd, J., Lloyd, H. M., Fitzpatrick, R. M., & Peters, M. (2017) · BMC Psychiatry · doi:10.1186/s12888-017-1418-8 · Cited by 26 · see citing works
Predicting time to relapse in patients with schizophrenia according to patients’ relapse history: a historical cohort study using real-world data in Sweden
Jørgensen, K. T., Bøg, M., Kabra, M., Simonsen, J., Adair, M., & Jönsson, L. (2021) · BMC Psychiatry · doi:10.1186/s12888-021-03634-z · Cited by 28 · see citing works
“This study provides further evidence of the progressive nature of schizophrenia, and emphasises the importance of providing early, effective, and tolerable treatment options that better meet a patient’s individual needs, to enable treatment adherence, recovery and prevent future relapses, which is consistent with prev…”
Result
Adherence in adults with type 1 diabetes mellitus correlates with treatment satisfaction but not with adverse events
Hendrychova, T., Vytrisalova, M., Smahelova, Vlček, J., & Kubena (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s47750 · Cited by 25 · see citing works
“12,18 In contrast to other chronic diseases, 31,32 adherence in adults with type 1 diabetes did not correlate with adverse events during treatment.”
Influencing factors and their relationships of risk perception and decision-making behaviour of polypharmacy in patients with chronic diseases: a qualitative descriptive study
Liu, Y., Wang, R., Huang, R., Cao, Y., Wang, J., & Feng, D. (2021) · BMJ Open · doi:10.1136/bmjopen-2020-043557 · Cited by 25 · see citing works
Adverse Drug Reactions Associated with Antipsychotics, Antidepressants, Mood Stabilizers, and Stimulants
Givens, C. (2016) · Nursing Clinics of North America · doi:10.1016/j.cnur.2016.01.013 · Cited by 25 · see citing works
Reduced sexual dysfunction with aripiprazole once-monthly versus paliperidone palmitate
Potkin, S. G., Loze, J.-Y., Forray, C., Baker, R. A., Sapin, C., Peters-Strickland, T. S., Beillat, M., Nylander, A., Hertel, P., Andersen, H. S., et al. (2017) · International Clinical Psychopharmacology · doi:10.1097/yic.0000000000000168 · Cited by 24 · see citing works
“Furthermore, patients with schizophrenia who report side effects are less likely to adhere to medication (Dibonaventura et al., 2012).”
Background
Impact of adverse reactions to first-generation antipsychotics on treatment adherence in outpatients with schizophrenia: a cross-sectional study
Bahta, M., Ogbaghebriel, A., Russom, M., Tesfamariam, E. H., & Berhe, T. (2021) · Annals of General Psychiatry · doi:10.1186/s12991-021-00348-0 · Cited by 24 · see citing works
“Association of specific adverse effect categories and non-adherence found in the present study is in line with some studies, which reported extrapyramidal [9, 15, 21, 22], hormonal [8, 9, 15], psychic [8, 9, 15, 18], and miscellaneous reactions such as weight gain [9] as determinants of non-adherence.”
Result
Factors associated with complete discontinuation of medication among patients with schizophrenia in the year after hospital discharge
Zhou, Y., Rosenheck, R., Mohamed, S., Ning, Y., & He, H. (2017) · Psychiatry Research · doi:10.1016/j.psychres.2017.01.036 · Cited by 23 · see citing works
“Thirdly, medication side effects were not assessed in the present study, which previous research suggests can be an important reason for non-adherence to prescribed mediation regimens (Dibonaventura et al., 2012).”
Background
S3-Leitlinie: Lungenerkrankung bei Mukoviszidose – Modul 2: Diagnostik und Therapie bei der chronischen Infektion mit Pseudomonas aeruginosa
Schwarz, C., Schulte-Hubbert, B., Bend, J., Abele‐Horn, M., Baumann, I. G., Bremer, W., Brunsmann, F., Dieninghoff, D., Eickmeier, O., Ellemunter, H., et al. (2018) · Pneumologie · doi:10.1055/s-0044-100191 · Cited by 24 · see citing works
Anaemia and physical and mental health in the very old: An individual participant data meta-analysis of four longitudinal studies of ageing
Palapar, L., Kerse, N. M., Rolleston, A. K., den Elzen, W. P. J., Gussekloo, J., Blom, J. W., Robinson, L. A., Martin-Ruiz, C. M., Duncan, R. C., Arai, Y., et al. (2020) · Age and Ageing · doi:10.1093/ageing/afaa178 · Cited by 24 · see citing works
4-Methoxycinnamic acid attenuates schizophrenia-like behaviors induced by MK-801 in mice
Jeong, Y., Bae, H. J., Park, K., Bae, H. J., Yang, X., Cho, Y.-J., Jung, S. Y., Jang, D. S., & Ryu, J. H. (2021) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2021.114864 · Cited by 23 · see citing works
Explaining Attitudes and Adherence to Antipsychotic Medication: The Development of a Process Model
Wiesjahn, M., Jung, E., Lamster, F., Rief, W., & Lincoln, T. M. (2014) · Schizophrenia Research and Treatment · doi:10.1155/2014/341545 · Cited by 23 · see citing works
“In support of this explanation, recent studies in patientswith psychotic disorders [20, 21] and in other populations [22] applied standardized assessments of side effects and found them to be consistently related to lower medication adherence.”
Result
Prevalence of Antipsychotic Drug Non Adherence and Associated Factors Among Patients with Schizophrenia Attending at Amanuel Mental Specialized Hospital, Addis Ababa, Ethiopia: Institutional Based Cross Sectional Study
Girma, S., Abdisa, E., & Fikadu, T. (2017) · Health Science Journal · doi:10.21767/1791-809x.1000520 · Cited by 22 · see citing works
“Similarly another study indicated patient having extra pyramidal and psychic side effects and sedation were found to be statistically significantly associated with non-adherence [23].”
Result
Effects of Berberine on Gut Microbiota in Patients with Mild Metabolic Disorders Induced by Olanzapine
Pu, Z., Sun, Y., Jiang, H., Hou, Q., Yan, H., Wen, H., & Li, G. (2021) · The American Journal of Chinese Medicine · doi:10.1142/s0192415x21500920 · Cited by 23 · see citing works
A psychological flexibility model of medication adherence in psychotic-spectrum disorders
Moitra, E., & Gaudiano, B. A. (2016) · Journal of Contextual Behavioral Science · doi:10.1016/j.jcbs.2016.10.003 · Cited by 22 · see citing works
Perspectives on medicine adherence in service users and carers with experience of legally sanctioned detention and medication: A qualitative study
Gault, I., Gallagher, & Chambers (2013) · Patient Preference and Adherence · doi:10.2147/ppa.s44894 · Cited by 21 · see citing works
“Although many mental health service users are prone to nonadherence, most concern around nonadherence is directed at severe mental illnesses such as schizophrenia.(4) A review of the literature concludes that the situation has not improved over the past 30 years.”
Background
Medication Management Frameworks in the Context of Self-Management: A Scoping Review
Cadel, L., Cimino, S. R., von den Baumen, T. R., James, K. A., McCarthy, L. M., & Guilcher, S. J. T. (2021) · Patient Preference and Adherence · doi:10.2147/ppa.s308223 · Cited by 20 · see citing works
Effects of the Nursing Psychoeducation Program on the Acceptance of Medication and Condition-Specific Knowledge of Patients with Schizophrenia
Matsuda, M., & Kohno, A. (2016) · Archives of Psychiatric Nursing · doi:10.1016/j.apnu.2016.03.008 · Cited by 21 · see citing works
Medication-related factors of non adherence among patients with schizophrenia and bipolar disorder: Outcome of a cross-sectional survey in Maiduguri, North-eastern Nigeria
Ibrahim, W, A., Pindar, K, S., Yerima, M, M., Rabbebe, B, I., Shehu, S, et al. (2015) · Journal of Neuroscience and Behavioral Health · doi:10.5897/jnbh2015.0128 · Cited by 20 · see citing works
“These medication-related factors include dosing regimen, side effect profiles, fear of addiction potentials, and concerns about drug-drug interactions (Weiden and Miller, 2001; DiBonaventura et al., 2012; Higashi et al., 2013; Caldeira et al., 2014; Eticha et al., 2015).”
BackgroundResult
Antipsychotic medication side effects knowledge amongst registered mental health nurses in England: A national survey
Begum, F., Mutsatsa, S. H., Gul, N., Thomas, B., & Flood, C. (2020) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12600 · Cited by 19 · see citing works
Schizophrenia through the carers' eyes: results of a European cross‐sectional survey
Svettini, A., Johnson, B., Magro, C., SAUNDERS, J. R., Jones, K., Silk, S., Hargarter, L., & Schreiner, A. (2015) · Journal of Psychiatric and Mental Health Nursing · doi:10.1111/jpm.12209 · Cited by 19 · see citing works
The incidence and economic burden of extrapyramidal symptoms in patients with schizophrenia treated with second generation antipsychotics in a Medicaid population
Kadakia, A., Brady, B. L., Dembek, C., Williams, G. R., & KENT, J. M. (2021) · Journal of Medical Economics · doi:10.1080/13696998.2021.2019501 · Cited by 18 · see citing works
Major Depressive Disorder (MDD) and Schizophrenia– Addressing Unmet Needs With Partial Agonists at the D2 Receptor: A Review
Mallet, J., Gorwood, P. A. P. M., Strat, Y. L., & Dubertret, C. (2019) · The International Journal of Neuropsychopharmacology · doi:10.1093/ijnp/pyz043 · Cited by 18 · see citing works
A clinical communication tool for the assessment of psychotropic medication side effects
Ashoorian, D. M., Davidson, R. M., Rock, D. J., Dragović, M., & Clifford, R. M. (2015) · Psychiatry Research · doi:10.1016/j.psychres.2015.10.022 · Cited by 18 · see citing works
“%) will discontinue pharmacological treatment potentially leading to illness relapse and re-hospitalization (DiBonaventura et al., 2012; Morrison et al., 2000; Lambert et al., 2004).”
Perceptions of treatment adherence among people with mental health problems and health care professionals
Kauppi, K., Hätönen, H. M., Adams, C. E., & Valimaki, M. A. (2014) · Journal of Advanced Nursing · doi:10.1111/jan.12567 · Cited by 17 · see citing works
The mediating effect of family function and medication adherence between symptoms and mental disability among Chinese patients with schizophrenia: a cross-sectional study
Sun, Y., Wang, M., Zhou, Y., Wang, L., Zhang, H., Lv, Y., & Li, G. (2018) · Psychology Health & Medicine · doi:10.1080/13548506.2018.1533248 · Cited by 18 · see citing works
“…reported to be associated with medication adherence includes symptoms(Katherine, Clifford, Mark, Ridha, & Ashork, 2012)，attitudes and low insight (Misdrahi, Petit, Blanc, Bayle, & Llorca, 2012), family support (Glick, Stekoll, & Hays, 2011) and medication side effects (Dibonaventura et al., 2012).”
Background
No pain, no gain revisited: the impact of positive and negative psychotherapy experiences on treatment outcome
Verkooyen, R., Broers, N. J., & Dandachi-FitzGerald, B. (2024) · Frontiers in Psychology · doi:10.3389/fpsyg.2024.1378456 · Cited by 18 · see citing works
Treatment Satisfaction Questionnaire for Medication (TSQM version 1.4): Ceiling and Floor Effects, Reliability, and Known-Group Validity in Brazilian Outpatients With Hypertension
Liberato, A. C. S., São‐João, T. M., Jannuzzi, F. F., Landaas, E. J., Wongchareon, K., & Rodrigues, R. C. M. (2020) · Value in Health Regional Issues · doi:10.1016/j.vhri.2020.07.578 · Cited by 17 · see citing works
Prospects of Probiotic Adjuvant Drugs in Clinical Treatment
Ren, Z., Hong, Y., Huo, Y., Peng, L., Lv, H., Chen, J., Wu, Z., & Wan, C. (2022) · Nutrients · doi:10.3390/nu14224723 · Cited by 17 · see citing works
“Currently, drug therapy is the most common means of remission in humans [3,4], but some are not particularly effective, or they cause additional damage to the body [5,6].”
Background
Group art therapy as adjunct therapy for the treatment of schizophrenic patients in day hospital
Mandić-Gajić, G. (2013) · Vojnosanitetski pregled · doi:10.2298/vsp1311065m · Cited by 17 · see citing works
Do cannabis use disorders increase medication non-compliance in schizophrenia?: United States Nationwide inpatient cross-sectional study
Patel, R. S., Sreeram, V., Vadukapuram, R., & Baweja, R. K. (2020) · Schizophrenia Research · doi:10.1016/j.schres.2020.11.002 · Cited by 16 · see citing works
G Protein–Coupled Receptor Heteromers in Brain: Functional and Therapeutic Importance in Neuropsychiatric Disorders
Sun, Y., Hasbi, A., & George, S. R. (2025) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-061724-080727 · Cited by 16 · see citing works
Dopamine partial agonists: a discrete class of antipsychotics
Taylor, D. M., Chithiramohan, R. N., Grewal, J., Gupta, A., Hansen, L. K., Reynolds, G. P., & Pappa, S. (2022) · International Journal of Psychiatry in Clinical Practice · doi:10.1080/13651501.2022.2151473 · Cited by 15 · see citing works
“Sedation is a side effect that is commonly strongly disliked by patients and their carers (Bourin & Briley, 2004; Dibonaventura et al., 2012) but it is often seen as beneficial particularly in the acute settings by clinicians though usually unnecessary and disadvantageous in the medium to long-term.”
Background
The impact of antipsychotic adherence on acute care utilization
Perkins, A. J., Khandker, R. K., Overley, A. M., Solid, C. A., Chekani, F., Roberts, A., Dexter, P. R., Boustani, M. A., & Hulvershorn, L. A. (2023) · BMC Psychiatry · doi:10.1186/s12888-023-04558-6 · Cited by 15 · see citing works
Paeonol, the active component of Cynanchum paniculatum, ameliorated schizophrenia-like behaviors by regulating the PI3K-Akt-GSK3β-NF-κB signalling pathway in MK-801-treated mice
Bae, H. J., Kim, J. Y., Choi, S., Kim, S.-Y., Kim, H. J., Cho, Y. E., Choi, Y.-Y., An, J.-Y., Cho, S.-Y., Ryu, J. H., et al. (2023) · Journal of Ethnopharmacology · doi:10.1016/j.jep.2023.116627 · Cited by 15 · see citing works
Side Effects of Psychotropic Medications Experienced by a Community Sample of People Living With Severe and Persistent Mental Illness
Collins, J. C., Wheeler, A., McMillan, S. S., Hu, J., El‐Den, S., Roennfeldt, H., & O’Reilly, C. L. (2024) · Health Expectations · doi:10.1111/hex.70122 · Cited by 15 · see citing works
“Side effects, such as weight gain, perceived impairment of cognition and sedation, may be so bothersome that people may choose to stop taking their medications, putting them at an increased risk of relapse and hospitalisation [10 – 13].”

RESEARCH ARTICLE Open Access
Dibonaventura, M. (2013)
Self-citation
The relationship between medication adherence and antipsychotic side-effects among schizophrenia outpatients
Fu, L. (2011) · Medical Journal of Chinese People's Health
Side Effects of Medications and Adherence to Medication in Patients Using Antipsychotics
Yılmaz, S., & Buzlu, S. (2019) · DOAJ (DOAJ: Directory of Open Access Journals)
Factors Related to Medication Adherence in Schizophrenia in an Outpatient Setting A Cross Sectional Study Conducted in Bandung West Java Indonesia
Amatayakul, A., Purnama, H., & Maneerat, S. (2016) · International Conference on Advances in Economics, Social Science and Human Behaviour Study (ESSHBS) · doi:10.15224/978-1-63248-098-9-33 · Cited by 2 · see citing works
Factors affecting adherence in patients with schizophrenia
Siddiqui, M., Pattojoshi, A., & Khess, C. R. J. (2015) · International Journal of Advances in Medicine · doi:10.18203/2349-3933.ijam20151483 · Cited by 5 · see citing works

Authors: DiBonaventura, M., Gabriel, S., Dupclay, L., Gupta, S., & Kim, E.
Affiliations: Kantar Health (United States) (US)
Novartis (United States) (US)
Corresponding author: DiBonaventura, Marco
ORCID: DiBonaventura, Marco
Gabriel, Susan
Gupta, Shaloo
Kim, Edward
Venue: BMC Psychiatry
Publisher: Springer Science and Business Media LLC
Published: 2012-03-20
Volume: 12
Issue: 1
Pages: 20-20
ISSN: 1471-244X (ISSN-L)
DOI: 10.1186/1471-244x-12-20
PMC: PMC3342101
OpenAlex: W2157910519
Cited by: 333
References: 31
Citations by year: 2026: 16 · 2025: 30 · 2024: 32 · 2023: 27 · 2022: 22 · 2021: 34 · 2020: 22 · 2019: 27 · 2018: 22 · 2017: 20 · 2016: 24 · 2015: 22 · 2014: 13 · 2013: 19 · 2012: 2
FWCI: 15.48
Type: journal article
Language: en
Open access: gold
doi.org
Licence: cc-by
www.springer.com/tdm (unspecified)
Locations: BMC Psychiatry (publishedVersion, cc-by)
PubMed Central (publishedVersion, cc-by)
PubMed (publishedVersion)
DOAJ (DOAJ: Directory of Open Access Journals) (submittedVersion, cc-by-sa)
Topics: Health Sciences › Medicine › Family Practice › Medication Adherence and Compliance
Health Sciences › Medicine › Psychiatry and Mental health › Schizophrenia research and treatment
Health Sciences › Medicine › Psychiatry and Mental health › Bipolar Disorder and Treatment
Keywords: schizophrenia, antipsychotic adverse effects, medication adherence, medication non-adherence, sedation, prolactin, metabolic side effects, health care utilization, hospitalization, emergency department visits, patient perspectives, community-dwelling patients, Morisky Medication Adherence Scale, health care costs, quality of life
MeSH terms: Adult, Attitude to Health, Cross-Sectional Studies, Female, Health Surveys, Humans, Male, Middle Aged, Schizophrenia, Schizophrenic Psychology, Antipsychotic Agents, Medication Adherence

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

A patient perspective of the impact of medication side effects on adherence: results of a cross-sectional nationwide survey of patients with schizophrenia

Abstract

Integrity signals

Claims the paper makes

Claims other papers make about this one

Self-check

Cites

Cited by

Related

Record

About these checks